References
- Martin S I, Marty F M, Fiumara K, Treon S P, Gribben J G, Baden L R. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43: 16–24
- Ghobrial I M, Otteman L A, White W L. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med 2003; 349: 2570–2572
- O'Brien S M, Kantarjian H M, Thomas D A, Cortes J, Giles F J, Wierda W G, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657–2663
- Roch N, Salameire D, Gressin R, Morand P, Epaulard O, Pavese P, et al. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome. Scand J Infect Dis 2007; 12: 1–4
- Kluin-Nelemans H C, Coenen J L, Boers J E, van Imhoff G W, Rosati S. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood 2008; 112: 1039–1041
- Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008; 42: 181–186
- Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi M K. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22: 261–281